{"id":"butaverine","rwe":[{"pmid":"18947253","year":"2008","title":"Zinc-mediated allylation and alkylation of aminals in the presence of TMSCl and diisopropylamine.","finding":"","journal":"The Journal of organic chemistry","studyType":"Clinical Study"}],"tags":[{"label":"butaverine","category":"class"},{"label":"Small Molecule","category":"modality"},{"label":"Active","category":"status"}],"phase":"phase_2","safety":{},"trials":[],"aliases":[],"patents":[],"pricing":[],"allNames":"butamiverine","offLabel":[],"synonyms":["butaverine","butamiverine","butaverine hydrochloride","butaverine HCl"],"timeline":[],"brandName":"Butamiverine","ecosystem":[],"mechanism":{"modality":"Small Molecule","drugClass":"butaverine","explanation":"Think of it like a key fitting into a lock. Butamiverine is like a key that fits into a specific lock on the surface of cells, called muscarinic acetylcholine receptors. When it fits in, it can affect how the cell responds to signals, which can help with certain medical conditions.","oneSentence":"Butamiverine works by interacting with muscarinic acetylcholine receptors in the body.","technicalDetail":"Butamiverine is a muscarinic receptor antagonist, which means it binds to and blocks the action of acetylcholine at muscarinic receptors, leading to a decrease in parasympathetic tone and a subsequent increase in sympathetic tone."},"commercial":{},"references":[{"id":1,"url":"https://drugcentral.org/drugcard/3692","fields":["approvals","synonyms","ATC","PK","indications","contraindications","DDIs","targets","patents","FAERS"],"source":"DrugCentral"},{"id":2,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=BUTAVERINE","fields":["publications"],"source":"PubMed/NCBI"}],"_enrichedAt":"2026-03-30T09:09:21.825550","biosimilars":[],"competitors":[],"genericName":"butaverine","indications":{"approved":[],"offLabel":[],"pipeline":[]},"drugCategory":"active","labelChanges":[],"relatedDrugs":[],"trialDetails":[],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"crossReferences":{"NDDF":"004188","UNII":"1I5O5WIU8X","CHEBI":"CHEBI:135203","INN_ID":"1407","UMLSCUI":"C0771071","ChEMBL_ID":"CHEMBL2106025","PUBCHEM_CID":"189889","SECONDARY_CAS_RN":"17824-89-4"},"formularyStatus":[],"_enricherVersion":"v2","developmentCodes":[],"ownershipHistory":[],"publicationCount":1,"therapeuticAreas":["Other"],"biosimilarFilings":[],"recentPublications":[{"date":"2008 Nov 21","pmid":"18947253","title":"Zinc-mediated allylation and alkylation of aminals in the presence of TMSCl and diisopropylamine.","journal":"The Journal of organic chemistry"}],"companionDiagnostics":[],"genericManufacturerList":[],"status":"active","companyName":"","companyId":"","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Butamiverine, also known as butaverine, is a small molecule drug in the butaverine class. Its exact target and mechanism of action are unknown, but it is believed to work by affecting the muscarinic acetylcholine receptors. Butamiverine is not FDA-approved for any indications, and its commercial status, including patent and generic availability, is unclear. Further research is needed to determine its safety and efficacy. As a result, butamiverine is not a widely recognized or used medication.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"partial","dataCompleteness":{"mechanism":true,"indications":false,"safety":false,"trials":false,"score":1}}